Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 26

1.

Human Plasmacytoid Dendritic Cells and Cutaneous Melanoma.

Monti M, Consoli F, Vescovi R, Bugatti M, Vermi W.

Cells. 2020 Feb 11;9(2). pii: E417. doi: 10.3390/cells9020417. Review.

2.

Tumor Infiltrating Neutrophils Are Enriched in Basal-Type Urothelial Bladder Cancer.

Mandelli GE, Missale F, Bresciani D, Gatta LB, Scapini P, Caveggion E, Roca E, Bugatti M, Monti M, Cristinelli L, Belotti S, Simeone C, Calza S, Melocchi L, Vermi W.

Cells. 2020 Jan 25;9(2). pii: E291. doi: 10.3390/cells9020291.

3.

The Atypical Receptor CCRL2 Is Essential for Lung Cancer Immune Surveillance.

Del Prete A, Sozio F, Schioppa T, Ponzetta A, Vermi W, Calza S, Bugatti M, Salvi V, Bernardini G, Benvenuti F, Vecchi A, Bottazzi B, Mantovani A, Sozzani S.

Cancer Immunol Res. 2019 Nov;7(11):1775-1788. doi: 10.1158/2326-6066.CIR-19-0168. Epub 2019 Sep 4.

PMID:
31484658
4.

Long Pentraxin-3 Follows and Modulates Bladder Cancer Progression.

Matarazzo S, Melocchi L, Rezzola S, Grillo E, Maccarinelli F, Giacomini A, Turati M, Taranto S, Zammataro L, Cerasuolo M, Bugatti M, Vermi W, Presta M, Ronca R.

Cancers (Basel). 2019 Aug 30;11(9). pii: E1277. doi: 10.3390/cancers11091277.

5.

Hyper-Activation of STAT3 Sustains Progression of Non-Papillary Basal-Type Bladder Cancer via FOSL1 Regulome.

Gatta LB, Melocchi L, Bugatti M, Missale F, Lonardi S, Zanetti B, Cristinelli L, Belotti S, Simeone C, Ronca R, Grillo E, Licini S, Bresciani D, Tardanico R, Chan SR, Giurisato E, Calza S, Vermi W.

Cancers (Basel). 2019 Aug 21;11(9). pii: E1219. doi: 10.3390/cancers11091219.

6.

FXYD5 (Dysadherin) upregulation predicts shorter survival and reveals platinum resistance in high-grade serous ovarian cancer patients.

Tassi RA, Gambino A, Ardighieri L, Bignotti E, Todeschini P, Romani C, Zanotti L, Bugatti M, Borella F, Katsaros D, Tognon G, Sartori E, Odicino F, Romualdi C, Ravaggi A.

Br J Cancer. 2019 Oct;121(7):584-592. doi: 10.1038/s41416-019-0553-z. Epub 2019 Aug 22.

PMID:
31434988
7.

Collapse of the Plasmacytoid Dendritic Cell Compartment in Advanced Cutaneous Melanomas by Components of the Tumor Cell Secretome.

Vescovi R, Monti M, Moratto D, Paolini L, Consoli F, Benerini L, Melocchi L, Calza S, Chiudinelli M, Rossi G, Bugatti M, Maio M, Fonsatti E, Farisoglio C, Simbolo M, Almici C, Verardi R, Scarpa A, Bergese P, Manganoni A, Facchetti F, Vermi W.

Cancer Immunol Res. 2019 Jan;7(1):12-28. doi: 10.1158/2326-6066.CIR-18-0141. Epub 2018 Nov 6. Erratum in: Cancer Immunol Res. 2019 Apr;7(4):693.

8.

NK-cell Editing Mediates Epithelial-to-Mesenchymal Transition via Phenotypic and Proteomic Changes in Melanoma Cell Lines.

Huergo-Zapico L, Parodi M, Cantoni C, Lavarello C, Fernández-Martínez JL, Petretto A, DeAndrés-Galiana EJ, Balsamo M, López-Soto A, Pietra G, Bugatti M, Munari E, Marconi M, Mingari MC, Vermi W, Moretta L, González S, Vitale M.

Cancer Res. 2018 Jul 15;78(14):3913-3925. doi: 10.1158/0008-5472.CAN-17-1891. Epub 2018 May 11.

9.

slan+ Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP.

Vermi W, Micheletti A, Finotti G, Tecchio C, Calzetti F, Costa S, Bugatti M, Calza S, Agostinelli C, Pileri S, Balzarini P, Tucci A, Rossi G, Furlani L, Todeschini G, Zamò A, Facchetti F, Lorenzi L, Lonardi S, Cassatella MA.

Cancer Res. 2018 Jul 1;78(13):3544-3559. doi: 10.1158/0008-5472.CAN-17-2344. Epub 2018 May 10.

10.

Natural Killer Cells Control Tumor Growth by Sensing a Growth Factor.

Barrow AD, Edeling MA, Trifonov V, Luo J, Goyal P, Bohl B, Bando JK, Kim AH, Walker J, Andahazy M, Bugatti M, Melocchi L, Vermi W, Fremont DH, Cox S, Cella M, Schmedt C, Colonna M.

Cell. 2018 Jan 25;172(3):534-548.e19. doi: 10.1016/j.cell.2017.11.037. Epub 2017 Dec 21.

11.

Two Distinct Myeloid Subsets at the Term Human Fetal-Maternal Interface.

Costa ML, Robinette ML, Bugatti M, Longtine MS, Colvin BN, Lantelme E, Vermi W, Colonna M, Nelson DM, Cella M.

Front Immunol. 2017 Oct 25;8:1357. doi: 10.3389/fimmu.2017.01357. eCollection 2017.

12.

The B-cell receptor controls fitness of MYC-driven lymphoma cells via GSK3β inhibition.

Varano G, Raffel S, Sormani M, Zanardi F, Lonardi S, Zasada C, Perucho L, Petrocelli V, Haake A, Lee AK, Bugatti M, Paul U, Van Anken E, Pasqualucci L, Rabadan R, Siebert R, Kempa S, Ponzoni M, Facchetti F, Rajewsky K, Casola S.

Nature. 2017 Jun 8;546(7657):302-306. doi: 10.1038/nature22353. Epub 2017 May 31.

PMID:
28562582
13.

FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.

Tassi RA, Todeschini P, Siegel ER, Calza S, Cappella P, Ardighieri L, Cadei M, Bugatti M, Romani C, Bandiera E, Zanotti L, Tassone L, Guarino D, Santonocito C, Capoluongo ED, Beltrame L, Erba E, Marchini S, D'Incalci M, Donzelli C, Santin AD, Pecorelli S, Sartori E, Bignotti E, Odicino F, Ravaggi A.

J Exp Clin Cancer Res. 2017 May 8;36(1):63. doi: 10.1186/s13046-017-0536-y.

14.

An adaptive signaling network in melanoma inflammatory niches confers tolerance to MAPK signaling inhibition.

Young HL, Rowling EJ, Bugatti M, Giurisato E, Luheshi N, Arozarena I, Acosta JC, Kamarashev J, Frederick DT, Cooper ZA, Reuben A, Gil J, Flaherty KT, Wargo JA, Vermi W, Smith MP, Wellbrock C, Hurlstone A.

J Exp Med. 2017 Jun 5;214(6):1691-1710. doi: 10.1084/jem.20160855. Epub 2017 Apr 27.

15.

Identification of novel follicular dendritic cell sarcoma markers, FDCSP and SRGN, by whole transcriptome sequencing.

Lorenzi L, Döring C, Rausch T, Benes V, Lonardi S, Bugatti M, Campo E, Cabeçadas J, Simonitsch-Klupp I, Borges A, Mehta J, Agostinelli C, Pileri SA, Facchetti F, Hansmann ML, Hartmann S.

Oncotarget. 2017 Mar 7;8(10):16463-16472. doi: 10.18632/oncotarget.14864.

16.

Correction: slanDCs/M-DC8+ cells constitute a distinct subset of dendritic cells in human tonsils.

Micheletti A, Finotti G, Calzetti F, Lonardi S, Zoratti E, Bugatti M, Stefini S, Vermi W, Cassatella MA.

Oncotarget. 2016 Oct 4;7(40):66323. doi: 10.18632/oncotarget.12418. No abstract available.

17.

Truncating Prolactin Receptor Mutations Promote Tumor Growth in Murine Estrogen Receptor-Alpha Mammary Carcinomas.

Griffith OL, Chan SR, Griffith M, Krysiak K, Skidmore ZL, Hundal J, Allen JA, Arthur CD, Runci D, Bugatti M, Miceli AP, Schmidt H, Trani L, Kanchi KL, Miller CA, Larson DE, Fulton RS, Vermi W, Wilson RK, Schreiber RD, Mardis ER.

Cell Rep. 2016 Sep 27;17(1):249-260. doi: 10.1016/j.celrep.2016.08.076.

18.

TLR Signalling Pathways Diverge in Their Ability to Induce PGE2.

Salvi V, Vaira X, Gianello V, Vermi W, Bugatti M, Sozzani S, Bosisio D.

Mediators Inflamm. 2016;2016:5678046. doi: 10.1155/2016/5678046. Epub 2016 Aug 18.

19.

Identical TP53 mutations in pelvic carcinosarcomas and associated serous tubal intraepithelial carcinomas provide evidence of their clonal relationship.

Ardighieri L, Mori L, Conzadori S, Bugatti M, Falchetti M, Donzelli CM, Ravaggi A, Odicino FE, Facchetti F.

Virchows Arch. 2016 Jul;469(1):61-9. doi: 10.1007/s00428-016-1933-x. Epub 2016 Apr 8.

PMID:
27059324
20.

slanDCs/M-DC8+ cells constitute a distinct subset of dendritic cells in human tonsils [corrected].

Micheletti A, Finotti G, Calzetti F, Lonardi S, Zoratti E, Bugatti M, Stefini S, Vermi W, Cassatella MA.

Oncotarget. 2016 Jan 5;7(1):161-75. doi: 10.18632/oncotarget.6660. Erratum in: Oncotarget. 2016 Oct 4;7(40):66323.

Supplemental Content

Loading ...
Support Center